SINGAPORE (Sept 18): CIMB Research is upgrading its call on Raffles Medical Group (RMG) to “add” from “reduce” with a lower price target of $1.21 from $1.25 previously on the belief that the stock is looking attractive to gain exposure to the growing China healthcare market, as gestation woes have been largely priced in. 

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.


  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply